Technical Analysis for MBIO - Mustang Bio, Inc.

Grade Last Price % Change Price Change
F 1.04 9.47% 0.09
MBIO closed up 9.47 percent on Monday, March 18, 2024, on 1.44 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 27
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 9.47%
180 Bearish Setup Bearish Swing Setup 9.47%
Calm After Storm Range Contraction 9.47%
Lower Bollinger Band Walk Weakness 9.47%
Wide Bands Range Expansion 9.47%

   Recent Intraday Alerts

Alert Time
Up 1 ATR about 14 hours ago
Up 10% about 17 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 5% about 18 hours ago
2x Volume Pace about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mustang Bio, Inc. Description

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Gene Therapy Virotherapy Cancer Cell Epidermal Growth Factor Receptor T Cell Chimeric Antigen Receptor Immunotherapy Products Cancer Immunotherapy Product Cellectis

Is MBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.17
52 Week Low 0.9014
Average Volume 146,271
200-Day Moving Average 2.76
50-Day Moving Average 1.31
20-Day Moving Average 1.23
10-Day Moving Average 1.15
Average True Range 0.11
RSI (14) 36.31
ADX 22.44
+DI 13.29
-DI 25.27
Chandelier Exit (Long, 3 ATRs) 1.16
Chandelier Exit (Short, 3 ATRs) 1.23
Upper Bollinger Bands 1.51
Lower Bollinger Band 0.95
Percent B (%b) 0.17
BandWidth 45.47
MACD Line -0.09
MACD Signal Line -0.05
MACD Histogram -0.0336
Fundamentals Value
Market Cap 8.71 Million
Num Shares 8.37 Million
EPS -8.93
Price-to-Earnings (P/E) Ratio -0.12
Price-to-Sales 0.00
Price-to-Book 3.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.29
Resistance 3 (R3) 1.27 1.17 1.25
Resistance 2 (R2) 1.17 1.11 1.18 1.24
Resistance 1 (R1) 1.11 1.07 1.14 1.12 1.22
Pivot Point 1.00 1.00 1.02 1.01 1.00
Support 1 (S1) 0.94 0.94 0.97 0.96 0.86
Support 2 (S2) 0.84 0.90 0.84 0.84
Support 3 (S3) 0.77 0.84 0.83
Support 4 (S4) 0.79